Burkitt Lymphoma (BL)
Burkitt lymphoma (BL) primarily affects B-cells, a type of white blood cell responsible for fighting infections. Our team of highly skilled and experienced scientists and researchers possess extensive knowledge in the field of Burkitt lymphoma (BL) therapy and animal model development. Our comprehensive range of customized services is designed to meet the unique needs of biology experts and researchers in this field.
Overview of Burkitt Lymphoma (BL)
- Definition of Burkitt Lymphoma (BL)
Burkitt lymphoma (BL) is a highly aggressive and rapidly growing form of non-Hodgkin lymphoma (NHL). The incidence of BL ranges from 1-9 cases per 100,000 population. BL is characterized by abnormal B-cells that divide and grow rapidly, leading to the formation of tumors. These tumors often occur in the abdomen but can also affect other parts of the body.
- Pathogenesis of Burkitt Lymphoma (BL)
The pathogenesis of Burkitt lymphoma (BL) involves genetic alterations that drive the development and progression of the disease. The most common genetic abnormality found in BL is the translocation of the MYC gene, which leads to its dysregulation. MYC is a proto-oncogene that plays a crucial role in cell growth and division. When dysregulated, MYC promotes uncontrolled cell proliferation, a hallmark of BL.
- Types of Burkitt Lymphoma (BL)
There are three main types of Burkitt Lymphoma (BL): endemic, sporadic, and immunodeficiency-associated.
- Endemic BL is prevalent in equatorial Africa, particularly among children infected with the Epstein-Barr virus (EBV), which plays a role in the development of this subtype.
- Sporadic BL is the most common type in the United Kingdom and other non-endemic regions.
- Immunodeficiency-associated BL occurs in individuals with a weakened immune system, such as those with HIV or those undergoing immunosuppressive therapy.
Fig.1 Molecular mechanisms and potential therapies of Burkitt lymphoma. (Zayac A. S., et al., 2020)Therapy Development of Burkitt Lymphoma (BL)
Targets of Burkitt Lymphoma (BL)
Understanding the molecular targets involved in the development of Burkitt Lymphoma (BL) is essential for the development of effective therapies. The dysregulation of MYC is a key target in BL, and efforts are underway to inhibit MYC function using inhibitors of proteins with bromodomain and extra-terminal motifs (BET/BRD). Additionally, inhibition of the B-cell receptor (BCR), PI3K, or SYK pathways, and disruption of metabolic pathways associated with BL are also being explored as potential therapeutic targets.
Therapeutic Approaches of Burkitt Lymphoma (BL)
Therapeutic approaches for Burkitt Lymphoma (BL) include a combination of immunotherapy and targeted therapies. Immunotherapies like chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers (BiTEs) are emerging as promising options, although their efficacy in BL is still being evaluated. Targeted therapies that inhibit specific pathways involved in BL pathogenesis, such as CDK4/6 inhibitors and PI3K/mTOR inhibitors, are also being explored in clinical trials.
Our Services
Our company offers a range of advantages in Burkitt lymphoma (BL) diagnostics and therapy development. With our extensive knowledge, tailored services, comprehensive therapy development, collaborative approach, commitment to quality and ethical standards, and timely project execution, we are your ideal partner for advancing research in Burkitt lymphoma (BL). Choose our company to unlock the full potential of your research and drive meaningful progress in the fight against Burkitt lymphoma (BL).
Platform Capabilities
Animal models serve a pivotal function in unraveling the intricate nuances of Burkitt lymphoma (BL) biology and gauging the effectiveness of prospective therapies. Our company holds distinctive expertise in crafting cutting-edge animal models that impeccably mirror the distinctive traits of Burkitt lymphoma (BL), thereby expediting preclinical research endeavors, including pharmacokinetics study and drug safety evaluation.
Animal Models of BL
- Providing BL cell line-derived xenograft model development services for in orthotopic assay of in vivo functional genomic (RNAi) screening.
- BL blasts are cryopreserved for the development of patient-derived xenograft models for target validation of drugs and testing of new therapies.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Zayac, Adam S., and Adam J. Olszewski. "Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy." Leukemia & lymphoma 61.8 (2020): 1784-1796.
- Kalisz, Kevin, et al. "An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence." Insights into imaging 10 (2019): 1-16.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.